Travere Therapeutics

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Travere Therapeutics reports robust earnings, eyes market expansion opportunities

Travere Therapeutics is on a solid financial footing with promising drug launches and clinical advancements. While facing regulatory and competitive challenges, the company's strategic focus on market expansion and product utilization presents significant growth opportunities. With a strong cash position and ongoing clinical developments, Travere is well-positioned for future success.

Travere Therapeutics reports strong Q1 performance amidst FILSPARI launch

Travere Therapeutics' Q1 performance was driven by strong FILSPARI sales and positive physician adoption.
Despite challenges in FSGS and HCU programs, regulatory flexibility and patient community evolution present opportunities.
Physician interest in FILSPARI data and payer coverage quality are key strengths for the successful launch.
Monitoring metrics and upcoming study readouts offer avenues for growth and optimization in rare disease treatments.

Travere Therapeutics reports strong Q2 performance and growth opportunities

Travere Therapeutics showcased strong performance with revenue growth and positive clinical results across key programs.
The company's strategic focus on core pipeline programs and divestment of non-core assets has bolstered its financial position.
Challenges include competitive dynamics, regulatory uncertainties, and the need for disciplined spending amidst growth opportunities.
Overall, Travere is well-positioned for future growth with promising pipeline programs and a focus on market expansion.

Travere Therapeutics reports strong Q3 performance and strategic advancements

Travere Therapeutics showcased strong operational and financial performance in Q3 2023, with advancements in key programs and positive regulatory engagements.
The company's strategic focus on rare disease treatments, patient education efforts, and regulatory alignment position it well for future growth.
Challenges in revenue forecasting, market positioning, and evolving treatment landscapes highlight areas for ongoing strategic focus and adaptation.
Opportunities in market expansion, revenue growth, program advancements, and patient engagement present avenues for continued success and impact.

Travere Therapeutics reports strong revenue growth and strategic advancements

Travere Therapeutics had a successful year with strong revenue growth and progress in key treatments
Filspari's performance in IgAN drove demand and revenue, positioning the company for further growth
Challenges include the DUPLEX study results and low innovation in the prescriber base
Opportunities lie in sNDA submissions, ongoing studies, and potential for full approval and broader label

Travere Therapeutics excels in Q1 with FILSPARI market success

Travere Therapeutics showcased strong performance and financial stability in Q1 2024, driven by FILSPARI's successful commercial launch and positive patient outcomes.
The company's focus on market adoption, regulatory milestones, and engagement strategies positions it for continued growth and potential inclusion in treatment guidelines.
Challenges in inventory management, regulatory compliance, and strategic alignment with stakeholders need to be addressed to capitalize on growth opportunities and maintain market leadership.

Travere Therapeutics excels in Q2 2024, poised for growth

Travere Therapeutics delivered a strong performance in Q2 2024, driven by FILSPARI's growth and positive regulatory developments.
While facing challenges in regulatory processes and market expansion, the company's solid financial position and ongoing initiatives position it well for future success.
Opportunities for growth abound through potential approvals, global expansion, and advancements in drug development programs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LOS ANGELES, CA / ACCESSWIRE / May 24, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or "the Company") (NASDAQ:TVTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Travere Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

BioMarin Pharmaceutical

Novo Nordisk

When it comes to possibilities of outsized rewards, few sectors can beat out biotech stocks with blockbuster potential. Fundamentally, the underlying sector enjoys a massive footprint.

3 Biotech Stocks With Blockbuster Potential

LOS ANGELES, CA / ACCESSWIRE / May 10, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or "the Company") (NASDAQ:TVTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Travere Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Travere Therapeutics, Inc. (NASDAQ:TVTX ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Naomi Eichenbaum - VP, IR Eric Dube - President, CEO and Director Jula Inrig - Chief Medical Officer Christopher Cline - CFO Peter Heerma - Chief Commercial Officer William Rote - SVP, Research and Development Conference Call Participants Maury Raycroft - Jefferies Greg Harrison - Bank of America Joseph Schwartz - SVB Securities Leon Wang - Barclays Liisa Bayko - Evercore ISI Laura Chico - Wedbush Securities Vamil Divan - Guggenheim Securities Alex Thompson - Stifel Ed Arce - HC Wainwright Operator Good day, and welcome to the Travere Therapeutics First Quarter 2023 Financial Results and Corporate Update Conference Call. Today's conference is being recorded.

Travere Therapeutics, Inc. (TVTX) Q1 2023 Earnings Call Transcript

Travere Therapeutics (TVTX) came out with a quarterly loss of $1.27 per share versus the Zacks Consensus Estimate of a loss of $1.18. This compares to loss of $1.20 per share a year ago.

Travere Therapeutics (TVTX) Reports Q1 Loss, Tops Revenue Estimates

FILSPARI™(sparsentan) granted accelerated approval by FDA for the reduction of proteinuria in IgA nephropathy (IgAN) on February 17 th , 2023; commercial launch underway

Travere Therapeutics Reports First Quarter 2023 Financial Results

Travere Therapeutics Inc.'s stock TVTX tumbled 35% Tuesday, after the company said data from a two-year study of a kidney drug failed to show a statistically significant improvement. The company said the Phase 3 trial of Sparsentan as a treatment for focal segmental glomerulosclerosis, or FSGS, did not meet the primary efficacy eGFR slope endpoint over 108 weeks of treatment.

Travere Therapeutics stock slides 35% after announcing disappointing results from 2-year trial of kidney drug

LOS ANGELES--(BUSINESS WIRE)---- $TVTX #TVTX--The Schall Law Firm Announces it is Investigating Claims Against Travere Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Travere Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Travere Therapeutics offered a disappointing update from a two-year study in kidney disease, and TVTX stock crashed Tuesday. The post Travere Crashes 29% On A Disappointing Update From A Two-Year Kidney Disease Test appeared first on Investor's Business Daily.

Travere Crashes 29% On A Disappointing Update From A Two-Year Kidney Disease Test

The DUPLEX Study did not achieve the primary efficacy eGFR slope endpoint over 108 weeks of treatment Secondary and topline exploratory endpoints trended favorably for sparsentan Treatment with sparsentan resulted in a reduction of proteinuria that was sustained through 108 weeks of treatment Sparsentan was well-tolerated with a consistent safety profile across all clinical trials conducted to date and comparable to irbesartan Company to host conference call and webcast today at 4:30pm ET SAN DIEGO, May 01, 2023 (GLOBE NEWSWIRE) --  Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced topline primary efficacy results from the pivotal Phase 3 DUPLEX Study of sparsentan, a Dual Endothelin Angiotensin Receptor Antagonist (DEARA), in focal segmental glomerulosclerosis (FSGS). At the end of the 108-week double-blind period, sparsentan was observed to have a 0.3 mL/min/1.73m2 per year (95% CI: -1.74, 2.41) favorable difference on eGFR total slope and a 0.9 mL/min/1.73m2 per year (95% CI: -1.27, 3.04) favorable difference on eGFR chronic slope compared to the active control irbesartan, which was not statistically significant.

Travere Therapeutics Announces Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis

Travere (TVTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Travere Therapeutics (TVTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

SAN DIEGO, April 26, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report first quarter 2023 financial results on Thursday, May 4, 2023, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.

Travere Therapeutics to Report First Quarter 2023 Financial Results

Travere: Pegtibatinase Takes The Lead In The HCU Treatment Race.

Travere: Pegtibatinase Takes The Lead In The HCU Treatment Race

The Filspari Paradox: Travere's Promising Drug Faces Early-Stage Challenges.

The Filspari Paradox: Travere's Promising Drug Faces Early-Stage Challenges

FILSPARI demonstrated a statistically significant, rapid, and sustained decline of proteinuria compared to the active control FILSPARI demonstrated a statistically significant, rapid, and sustained decline of proteinuria compared to the active control

Travere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023

Axsome Therapeutics

Sarepta Therapeutics

Axsome already has two approved drugs and could add two more in the near future. Sarepta has significant growth opportunities with its rare-disease drugs.

3 Up-and-Coming Growth Stocks to Buy Right Now

SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the interim analysis of efficacy and safety data from the ongoing Phase 3 PROTECT Study evaluating FILSPARI™ (sparsentan) in IgA nephropathy (IgAN) will be presented in late-breaking trial sessions at both the ISN World Congress of Nephrology in Bangkok, Thailand, March 30-April 2 (ISN-WCN), and NKF Spring Clinical Meetings in Austin, TX, April 11-15, 2023 (NKF).

Travere Therapeutics Announces Late-Breaker Presentations of the Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy at the ISN World Congress of Nephrology and NKF Spring Clinical Meetings 2023

SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company will present a quantitative systems pharmacology (QSP) model for predicting the effects of the investigational enzyme replacement therapy pegtibatinase, in classical homocystinuria (HCU), as well as real-world evidence on the prevalence and potential underdiagnosis and/or underreporting of HCU in the United States, at the 2023 Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting in Salt Lake City, UT, March 18-21, 2023. The Company and its collaborators will also provide presentations from the Company's ongoing longitudinal natural history study of people living with HCU, and HCU incidence estimates based on gnomAD database evaluation at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting in Salt Lake City, UT, March 14-18, 2023.

Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders 44th Annual Meeting and the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting 2023

SAN DIEGO, March 03, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the completion of its previously announced underwritten public offering of 9,703,750 shares of its common stock at a price to the public of $21.00 per share and pre-funded warrants to purchase 1,250,000 shares of its common stock at a price to the public of $20.9999 per pre-funded warrant, including 1,428,750 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares. All of the shares were sold by Travere. Including the option exercise, the aggregate gross proceeds from the offering were approximately $230.0 million, before deducting the underwriting discounts and commissions and offering expenses.

Travere Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants and Exercise in Full of Underwriters' Option to Purchase Additional Shares

Is now the time to load up on this struggling stock?

Could an FDA Approval Send This Stock Flying?

SAN DIEGO, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of an underwritten public offering of 8,275,000 shares of its common stock at a price to the public of $21.00 per share and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase 1,250,000 shares of its common stock at a price to the public of $20.9999 per pre-funded warrant. The exercise price of the pre-funded warrants is $0.0001 per share. All of the shares and pre-funded warrants are being sold by Travere. The gross proceeds from the offering are expected to be approximately $200.0 million, before deducting the underwriting discounts and commissions and offering expenses. The offering is expected to close on March 3, 2023, subject to customary closing conditions. In addition, Travere has granted the underwriters for the offering a 30-day option to purchase up to an additional 1,428,750 shares of its common stock at the public offering price, less the underwriting discounts and commissions.

Travere Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Travere Therapeutics, Inc. (NASDAQ:TVTX ) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ET Company Participants Naomi Eichenbaum - VP, IR Eric Dube - President, CEO & Director Jula Inrig - Chief Medical Officer Christopher Cline - CFO Peter Heerma - Chief Commercial Officer William Rote - SVP, Research & Development Conference Call Participants Gregory Harrison - Bank of America Merrill Lynch Maurice Raycroft - Jefferies Joseph Schwartz - SVB Securities Lachlan Hanbury-Brown - William Blair & Company Antonio Arce - H.C. Wainwright & Co. Carter Gould - Barclays Bank Liisa Bayko - Evercore ISI Alexander Thompson - Stifel, Nicolaus & Company Guyn Kim - Piper Sandler & Co. Laura Chico - Wedbush Securities Operator Good day, and welcome to the Travere Therapeutics Fourth Quarter and Full Year 2022 Financial Results and Corporate Update.

Travere Therapeutics, Inc. (TVTX) Q4 2022 Earnings Call Transcript

Travere (TVTX) delivered earnings and revenue surprises of 0.96% and 1.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Travere Therapeutics (TVTX) Reports Q4 Loss, Tops Revenue Estimates

Recently received U.S. FDA accelerated approval of FILSPARI™ (sparsentan), the first and only non-immunosuppressive therapy for the reduction of proteinuria in  IgA nephropathy (IgAN)

Travere Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

A high-value regulatory approval lit a fire underneath the biotech's shares this week.

News for Travere Therapeutics Stock (TVTX)